<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26418275</article-id>
<article-id pub-id-type="pmc">5545641</article-id>
<article-id pub-id-type="pii">tp2015142</article-id>
<article-id pub-id-type="doi">10.1038/tp.2015.142</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6</article-title>
<alt-title alt-title-type="running">Luteolin reduces serum IL-6 and TNF in autism</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tsilioni</surname>
<given-names>I</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taliou</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Francis</surname>
<given-names>K</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Theoharides</surname>
<given-names>T C</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="aff" rid="aff5">5</xref>
<xref ref-type="aff" rid="aff6">6</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Pediatrics, Athens University School of Medicine</institution>, Athens, <country>Greece</country></aff>
<aff id="aff3"><label>3</label><institution>Second Department of Psychiatry, Attikon General Hospital, Athens University School of Medicine</institution>, Athens, <country>Greece</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff5"><label>5</label><institution>Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff6"><label>6</label><institution>Department of Integrative Physiology and Pathobiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine</institution>, Boston, MA, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine</institution>, 136 Harrison Avenue, Suite J304, Boston, MA 02111, <country>USA</country>. E-mail: <email>theoharis.theoharides@tufts.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>09</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>09</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>9</month>
<year>2015</year>
</pub-date>
<volume>5</volume>
<issue>9</issue>
<fpage>e647</fpage>
<lpage></lpage>
<history>
<date date-type="received">
<day>05</day>
<month>06</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>07</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>08</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2015 Macmillan Publishers Limited</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>Macmillan Publishers Limited</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--author-paid-->
<license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
</license>
</permissions>
<abstract>
<p>Autism spectrum disorders (ASDs) have been associated with brain inflammation as indicated by microglia activation, as well as brain expression and increased plasma levels of interleukin-6 (IL-6) and tumor necrosis factor (TNF). Here we report that serum levels of IL-6 and TNF were elevated (61.95±94.76 pg ml<sup>−1</sup> and 313.8±444.3 pg ml<sup>−1</sup>, respectively) in the same cohort of patients with elevated serum levels of corticotropin-releasing hormone (CRH) and neurotensin (NT), while IL-9, IL-31 and IL-33 were not different from controls. The elevated CRH and NT levels did not change after treatment with a luteolin-containing dietary formulation. However, the mean serum IL-6 and TNF levels decreased significantly (<italic>P</italic>=0.036 and <italic>P</italic>=0.015, respectively) at the end of the treatment period (26 weeks) as compared with levels at the beginning; these decreases were strongly associated with children whose behavior improved the most after luteolin formulation treatment. Our results indicate that there are distinct subgroups of children within the ASDs that may be identifiable through serum levels of IL-6 and TNF and that these cytokines may constitute distinct prognostic markers for at least the beneficial effect of luteolin formulation.</p>
</abstract>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by impaired social interactions and communication, as well as stereotypic behaviors.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> The prevalence of ASDs is estimated to be 1 in 68 children.<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> As many as 50% of children with ASDs regress at 2–3 years old implying the involvement of some epigenetic triggers, such as high fever, infection,<sup><xref ref-type="bibr" rid="bib6">6</xref>, <xref ref-type="bibr" rid="bib7">7</xref></sup> trauma,<sup><xref ref-type="bibr" rid="bib8">8</xref></sup> environmental toxins<sup><xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref></sup> or stress.<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> In spite of the identification of a number of mutations in children with ASDs,<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> its pathogenesis remains unknown. Moreover there are no objective biomarkers for either diagnosis or prognosis making effective drug development difficult.</p>
<p>There appear to be distinct subgroups within the ASDs, including gastrointestinal problems,<sup><xref ref-type="bibr" rid="bib14">14</xref></sup> mitochondrial dysfunction<sup><xref ref-type="bibr" rid="bib15">15</xref></sup> and ‘allergic’ symptoms,<sup><xref ref-type="bibr" rid="bib16">16</xref></sup> especially food intolerance and eczema.<sup><xref ref-type="bibr" rid="bib17">17</xref></sup> However, no group has been identified by objective biomarkers. Increasing evidence indicates that brain inflammation is important in the pathogenesis of neuropsychiatric disorders<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref></sup> including ASDs. A recent paper reported microglia activation as a common finding in the brain of patients with ASDs.<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> Microglia can be activated by mast cells (MC),<sup><xref ref-type="bibr" rid="bib21">21</xref></sup> which have been implicated in ASDs.<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> In fact, the risk of ASDs appears to be 10 times higher in children with mastocytosis,<sup><xref ref-type="bibr" rid="bib23">23</xref></sup> a condition characterized by an increased number of activated MCs.<sup><xref ref-type="bibr" rid="bib24">24</xref></sup></p>
<p>We reported increased serum levels of the peptide neurotensin (NT) in children with ASDs.<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> NT is a vasoactive peptide isolated from the brain<sup><xref ref-type="bibr" rid="bib26">26</xref></sup> and is implicated in immunity.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> We recently reported that serum levels of corticotropin-releasing hormone (CRH), secreted under stress, were also elevated together with NT in children with ASDs.<sup><xref ref-type="bibr" rid="bib28">28</xref></sup> CRH increased vascular permeability<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> through a synergistic action with NT.<sup><xref ref-type="bibr" rid="bib29">29</xref></sup> Interactions among CRH, NT, microglia and MCs could contribute to brain inflammation.<sup><xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib31">31</xref></sup></p>
<p>Many children with ASDs have been reported to have ‘allergic-like’ symptoms<sup><xref ref-type="bibr" rid="bib32">32</xref></sup> implicating MC activation.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> Natural flavonoids, like luteolin and quercetin, exhibit potent anti-oxidant and anti-inflammatory activities<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> and inhibit the release of inflammatory mediators from human MCs.<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> Luteolin and its structurally related quercetin inhibit the release of histamine, leukotrienes, interleukin-8 (IL-8), IL-6 and tumor necrosis factor-alpha (TNF-α) from human cultured MCs<sup><xref ref-type="bibr" rid="bib36">36</xref>, <xref ref-type="bibr" rid="bib37">37</xref>, <xref ref-type="bibr" rid="bib38">38</xref></sup> and allergic inflammation.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> Moreover, luteolin inhibited IL-6 release from activated microglia<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> and reduced maternal IL-6-induced autism-like behavioral deficits related to social interactions in mice.<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> Luteolin also inhibits MC-dependent stimulation of activated T cells,<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> and is neuroprotective.<sup><xref ref-type="bibr" rid="bib43">43</xref></sup> It also inhibits stimulation of astrocytes,<sup><xref ref-type="bibr" rid="bib44">44</xref></sup> as well as microglial activation and proliferation,<sup><xref ref-type="bibr" rid="bib45">45</xref>, <xref ref-type="bibr" rid="bib46">46</xref>, <xref ref-type="bibr" rid="bib47">47</xref></sup> protects against thimerosal-induced inflammatory mediator release from MCs <sup><xref ref-type="bibr" rid="bib48">48</xref></sup> and methylmercury-induced mouse brain mitochondrial damage.<sup><xref ref-type="bibr" rid="bib49">49</xref></sup> One open-label clinical study showed that a luteolin-containing dietary formulation significantly improved sociability in children with ASDs.<sup><xref ref-type="bibr" rid="bib50">50</xref></sup></p>
<p>Here we report that serum IL-6 and TNF levels that were elevated in the children with ASDs in that study before treatment were significantly reduced at the end of the treatment period; moreover, this reduction strongly correlated with those children who improved by this luteolin dietary supplement.</p>
</sec>
<sec>
<title>Materials and Methods</title>
<p>Fasting blood was obtained from Caucasian children (34 male and 6 female, 4–10 years of age) on the entire ASDs who participated in an open-label clinical trial conducted at the Attikon General Hospital, Athens Medical School, Athens, Greece (registered at ClinicalTrials.gov, NCT 01847521).<sup><xref ref-type="bibr" rid="bib50">50</xref></sup> Children were diagnosed with ASDs based on clinical assessment and corroborated by meeting the cutoff scores on both the DSM-IV-TR symptom list and the autism diagnostic observation schedule (ADOS) algorithm. They were medication free prior to blood draw for at least 2 weeks for all psychotropic medications and 4 weeks for fluoxetine or depot neuroleptics. The exclusion criteria were: (1) Any genetic condition linked to ASDs (for example, Rett syndrome, Fragile X syndrome, tuberous sclerosis or focal epilepsy); (2) Any genetic syndrome involving the central nervous system, even if the link with ASDs was uncertain; (3) Any neurologic disorder involving pathology above the brain stem, other than uncomplicated non-focal epilepsy; (4) Contemporaneous evidence, or unequivocal retrospective evidence, of probable neonatal brain damage; (5) Clinically significant visual or auditory impairment, even after correction; (6) Any severe nutritional or psychological deprivation; (7) Systemic or mastocytosis (including urticaria pigmentosa); (8) History of upper airway diseases; (9) History of inflammatory diseases (for example, juvenile rheumatoid arthritis, inflammatory bowel disease); (10) History of allergies. Informed consent was obtained from all subjects. This protocol was approved by the Ethics Committee of Attikon General Hospital, Athens Medical School, Athens, Greece.</p>
<p>Children were administered the dietary formulation (NeuroProtek, GMPCertified, Tishcon, Salisbury, MD, USA) containing the liposomal flavonoids (mg per capsule): luteolin (100), quercetin (70) and the quercetin glucoside rutin (30) in olive fruit extract formulated by a good manufacturing practices–certified facility (Tishcon Laboratories, Westbury, NY, USA) under contract from Algonot (Sarasota, FL, USA; <ext-link ext-link-type="uri" xlink:href="http://www.algonot.com" xmlns:xlink="http://www.w3.org/1999/xlink">www.algonot.com</ext-link>). Quercetin and rutin were added to the formulation as ‘decoys’ to keep the intestinal and liver enzymes occupied to allow luteolin to escape metabolism and reach the brain.</p>
<p>Serum was also collected from normally developing, healthy children, unrelated to the ASDs subjects, who were seen for routine health visits at the Pediatric Department of the Social Security Administration (IKA) polyclinic. Serum samples were labeled only with a code number, the age and sex of the subjects. All ASDs and control blood samples were prepared immediately and serum was stored in −80 °C. Samples were then transported on dry ice to Boston for analysis.</p>
<sec>
<title>Assessment of serum cytokine levels</title>
<p>IL-6, IL-9, IL-31, IL-33 and TNF levels were determined with commercially available enzyme-immunosorbent assay (ELISA) kits (R&amp;D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Prior to analysis, the data were validated and inspected for outliers. The results are presented as scattergrams with symbols representing individual data points and the horizontal lines representing the mean for each group. Normality of distribution was checked with the Shapiro–Wilk’s test. Comparison between the healthy control and the ASDs groups was performed using Mann–Whitney <italic>U</italic>-tests. Comparison of the ASDs group at baseline and at endpoint was performed using Wilcoxon matched pair test. The effect of Vineland Adaptive Behavior Scale (VABS) domains outcome in time was investigated using a general linear model for repeated measurements. A result was considered significant at a <italic>P</italic>-value &lt;0.05. The analysis was performed by using the GraphPad Prism version 5.0 software (GraphPad Software, San Diego, CA, USA).</p>
</sec>
</sec>
<sec>
<title>Results</title>
<p>There was no statistical difference in serum levels of IL-9, IL-31 and IL-33 between ASDs and normotypic controls (results not shown).</p>
<p>Serum IL-6 levels were elevated (61.95±94.76 pg ml<sup>−1</sup>) in children with ASDs as compared with normotypic controls (23.20±16.31 pg ml<sup>−1</sup>), but this increase did not reach statistical significance (<xref ref-type="fig" rid="fig1">Figure 1a</xref>).</p>
<p>Nevertheless, serum IL-6 levels were significantly (<italic>P</italic>=0.036) lower (14.68±19.22 pg ml<sup>−1</sup>) in children with ASDs after treatment with luteolin in comparison to their levels before the beginning of treatment (61.95±94.76 pg ml<sup>−1</sup>) (<xref ref-type="fig" rid="fig1">Figure 1b</xref>).</p>
<p>Serum TNF levels were significantly (<italic>P</italic>=0.045) elevated (313.8±444.3 pg ml<sup>−1</sup>) in children with ASDs as compared with normotypic controls (52.78±34.62 pg ml<sup>−1</sup>) (<xref ref-type="fig" rid="fig2">Figure 2a</xref>).</p>
<p>These elevated serum TNF levels were significantly (<italic>P</italic>=0.015) lower (139.6±181.5 pg ml<sup>−1</sup>) in children with ASDs after treatment with luteolin in comparison to their levels before the beginning of treatment (313.8±444.3 pg ml<sup>−1</sup>) (<xref ref-type="fig" rid="fig2">Figure 2b</xref>).</p>
<p>There were two clusters of ASD children with low and high serum IL-6 and TNF levels indicating two subgroups. Low IL-6 and TNF levels are those below the mean, while high IL-6 and TNF levels are those above the mean. The ASDs children who had both high serum IL-6 and TNF levels were the same (<italic>n</italic>=10).</p>
<p>The improvement in the VABS age-equivalent scores for these 10 ASDs children was significant (<italic>P</italic>&lt;0.05) for all domains (<xref ref-type="table" rid="tbl1">Table 1</xref>). The VABS composite score was also significantly higher at the end of the study. These data indicate a positive effect of the luteolin dietary supplement on the adaptive functioning of this subgroup of ASDs children. More specifically these children gained 9.73 months in the communication domain, 6.64 months in daily living skills and 8.09 months in the social domain.</p>
</sec>
<sec>
<title>Discussion</title>
<p>Our study shows two clusters of ASD children with low and high serum IL-6 and TNF levels, indicating two subgroups. Moreover, the ASD children who had both high serum IL-6 and TNF levels were the same (<italic>n</italic>=10). We further show that the children with ASDs in which the elevated serum IL-6 and TNF levels decreased at the end of the treatment period with a luteolin formulation, were the ones whose behavior improved the most.</p>
<p>There is evidence indicating that certain cytokines can impair neurodevelopment and behavior<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib51">51</xref></sup> and that microglia activation and inflammation is involved in the pathogenesis of neuropsychiatric diseases<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib51">51</xref></sup> including ASDs.<sup><xref ref-type="bibr" rid="bib52">52</xref>, <xref ref-type="bibr" rid="bib53">53</xref></sup> IL-6 can directly alter neuronal activity, proliferation and survival that may impact behavior.<sup><xref ref-type="bibr" rid="bib54">54</xref></sup> IL-6 has also physiological and pathological effects on learning and memory.<sup><xref ref-type="bibr" rid="bib55">55</xref></sup> Increased gene expression of IL-6 was noted in postmortem specimens of the temporal cortex of the brain of individuals with ASDs<sup><xref ref-type="bibr" rid="bib56">56</xref></sup> and increased protein level of IL-6 was found in the brain and cerebrospinal fluid of individuals with ASDs.<sup><xref ref-type="bibr" rid="bib57">57</xref></sup> In agreement with these findings, IL-6 was significantly increased in the frontal cortex and cerebellum of ASD patients as compared with the age-matched controls.<sup><xref ref-type="bibr" rid="bib58">58</xref></sup> IL-6 may derive from microglia cells, which are activated in ASDs.<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> Consistent with our results is a previously reported meta-analysis of increased IL-6 concentrations in peripheral blood in ASD participants compared with healthy controls.<sup><xref ref-type="bibr" rid="bib59">59</xref></sup> It is of interest that acute restraint stress of mice led to increased serum IL-6, which was entirely MC dependent.<sup><xref ref-type="bibr" rid="bib60">60</xref></sup> IL-1β can stimulate selective release of IL-6 from MCs.<sup><xref ref-type="bibr" rid="bib61">61</xref></sup></p>
<p>In the present study, we also found significantly increased serum TNF levels in children with ASDs in comparison to healthy controls. Another study showed increased TNF production in peripheral blood mononuclear cells of autistic subjects after stimulation with polyhydroxyalkanoates and tetanus.<sup><xref ref-type="bibr" rid="bib62">62</xref></sup> TNF was increased almost 50 times in the cerebrospinal fluid of ASD children.<sup><xref ref-type="bibr" rid="bib63">63</xref></sup> Brain MCs can secrete TNF.<sup><xref ref-type="bibr" rid="bib64">64</xref></sup> Both TNF and IL-6 expression has been documented in brains of children with ASDs<sup><xref ref-type="bibr" rid="bib65">65</xref></sup> and IL-6 has been implicated in an animal ‘model’ of autism.<sup><xref ref-type="bibr" rid="bib7">7</xref></sup> In this context, it is particularly important that MCs are the only cells that store preformed TNF, which they can secrete rapidly.<sup><xref ref-type="bibr" rid="bib66">66</xref></sup> MCs are the only cells that release IL-6 in response to stress.<sup><xref ref-type="bibr" rid="bib60">60</xref></sup> Preformed TNF is secreted from MCs<sup><xref ref-type="bibr" rid="bib67">67</xref></sup> and stimulates T-cell activation.<sup><xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib68">68</xref></sup> TNF has been linked with neurite growth and the regulation of homeostatic synaptic plasticity in the hippocampus.<sup><xref ref-type="bibr" rid="bib69">69</xref></sup></p>
<p>One study also showed increased serum levels of IL-17 in children with ASDs.<sup><xref ref-type="bibr" rid="bib70">70</xref></sup> Another study showed increased plasma IL-1β and IL-17, but only in children with ASD and regression; children with ASD and GI issues had higher plasma IL-1β and IL-6, but not TNF. TNF and IL-17 seem to act together in perpetuating the inflammatory process.<sup><xref ref-type="bibr" rid="bib71">71</xref>, <xref ref-type="bibr" rid="bib72">72</xref></sup> MC-derived IL-6 and transforming growth factor beta (TGFβ) induce the development of Th-17 cells through dendritic cell maturation;<sup><xref ref-type="bibr" rid="bib73">73</xref></sup> Moreover, MCs secrete IL-17, themselves.<sup><xref ref-type="bibr" rid="bib74">74</xref></sup></p>
<p>Here we report that treatment with a luteolin-containing dietary formulation normalized serum IL-6 and TNF in those children that showed the most benefit from the use of luteolin.</p>
<p>We recently reported that the structural analog of luteolin 3′,4′,5,7-tetramethoxy flavone was more potent than luteolin in its ability to inhibit mediator release from human MCs.<sup><xref ref-type="bibr" rid="bib35">35</xref></sup></p>
<p>Luteolin is structurally closely related to 7,8-dihydroflavone, which was shown to have brain-derived neurotrophic factor (BDNF)-like activity.<sup><xref ref-type="bibr" rid="bib75">75</xref></sup> In fact, absence of BDNF was associated with autistic-like-behavior in mice, while 7,8-dihydroflavone administration reduced symptoms in a mouse model of Rett syndrome,<sup><xref ref-type="bibr" rid="bib76">76</xref></sup> most patients with which have symptoms of ASDs.<sup><xref ref-type="bibr" rid="bib77">77</xref></sup></p>
<p>We believe this is the first time that objective biomarkers can (a) distinguish a subgroup of children with ASDs and (b) their reduced level correlate with a favorable clinical outcome, following administration of a natural anti-inflammatory compound. Flavonoids are considered generally safe<sup><xref ref-type="bibr" rid="bib78">78</xref>, <xref ref-type="bibr" rid="bib79">79</xref>, <xref ref-type="bibr" rid="bib80">80</xref></sup> and are being discussed as possible treatment of central nervous system disorders<sup><xref ref-type="bibr" rid="bib81">81</xref></sup> that may involve brain inflammation in response to environmental triggers. One obvious question is how much of the luteolin may reach the brain because flavonoids purely absorb orally and are extensively metabolized.<sup><xref ref-type="bibr" rid="bib82">82</xref>, <xref ref-type="bibr" rid="bib83">83</xref>, <xref ref-type="bibr" rid="bib84">84</xref></sup> Unfortunately, children with ASDs are prescribed many other supplements and psychotropic drugs that may have unwanted drug interactions.<sup><xref ref-type="bibr" rid="bib85">85</xref></sup> One way to deliver luteolin directly to the brain would be through intranasal administration through the cribriform plexus as shown before for another compound.<sup><xref ref-type="bibr" rid="bib86">86</xref></sup></p>
</sec>
</body>
<back>
<ack>
<p>This study was supported in part by the Autism Research Institute, the Jane Botsford Johnson Foundation and the BHARE Foundation. We thank Dr AK Theoharides for collecting the human normotypic serum samples and Mrs Smaro Panagiotidou for her word processing skills.</p>
<p>
<bold>Disclaimer</bold>
</p>
<p>TCT is the inventor of US patent No. 8,268,365 and US patent No. 20110027397 A1 on methods of treating autism spectrum disorders and compositions for same.</p>
</ack>
<fn-group>
<fn fn-type="COI-statement">
<p>The authors declare no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<ref id="bib1">
<mixed-citation publication-type="journal">Fombonne E. <article-title>Epidemiology of pervasive developmental disorders</article-title>. <source/>Pediatr Res
<year>2009</year>; <volume>65</volume>: <fpage>591</fpage>–598.<pub-id pub-id-type="pmid">19218885</pub-id></mixed-citation>
</ref>
<ref id="bib2">
<mixed-citation publication-type="journal">Johnson CP, Myers SM. <article-title>Identification and evaluation of children with autism spectrum disorders</article-title>. <source/>Pediatrics
<year>2007</year>; <volume>120</volume>: <fpage>1183</fpage>–1215.<pub-id pub-id-type="pmid">17967920</pub-id></mixed-citation>
</ref>
<ref id="bib3">
<mixed-citation publication-type="journal">McPartland J, Volkmar FR. <article-title>Autism and related disorders</article-title>. <source/>Handb Clin Neurol
<year>2012</year>; <volume>106</volume>: <fpage>407</fpage>–418.<pub-id pub-id-type="pmid">22608634</pub-id></mixed-citation>
</ref>
<ref id="bib4">
<mixed-citation publication-type="journal">Abrahams BS, Geschwind DH. <article-title>Advances in autism genetics: on the threshold of a new neurobiology</article-title>. <source/>Nat Rev Genet
<year>2008</year>; <volume>9</volume>: <fpage>341</fpage>–355.<pub-id pub-id-type="pmid">18414403</pub-id></mixed-citation>
</ref>
<ref id="bib5">
<mixed-citation publication-type="other">Centers for Disease Control and Prevention. CDC estimates 1 in 68 children has been identified with autism spectrum disorder, 2014. http://wwwcdcgov/media/releases/2014/p0327-autism-spectrum-disorder html.</mixed-citation>
</ref>
<ref id="bib6">
<mixed-citation publication-type="journal">Hornig M, Weissenbock H, Horscroft N, Lipkin WI. <article-title>An infection-based model of neurodevelopmental damage</article-title>. <source/>Proc Natl Acad Sci USA
<year>1999</year>; <volume>96</volume>: <fpage>12102</fpage>–12107.<pub-id pub-id-type="pmid">10518583</pub-id></mixed-citation>
</ref>
<ref id="bib7">
<mixed-citation publication-type="journal">Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH. <article-title>Modeling an autism risk factor in mice leads to permanent immune dysregulation</article-title>. <source/>Proc Natl Acad Sci USA
<year>2012</year>; <volume>109</volume>: <fpage>12776</fpage>–12781.<pub-id pub-id-type="pmid">22802640</pub-id></mixed-citation>
</ref>
<ref id="bib8">
<mixed-citation publication-type="journal">Blenner S, Reddy A, Augustyn M. <article-title>Diagnosis and management of autism in childhood</article-title>. <source/>BMJ
<year>2011</year>; <volume>343</volume>: <fpage>d6238</fpage>.<pub-id pub-id-type="pmid">22021467</pub-id></mixed-citation>
</ref>
<ref id="bib9">
<mixed-citation publication-type="journal">Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. <article-title>How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis</article-title>. <source/>NeuroToxicol
<year>2008</year>; <volume>29</volume>: <fpage>190</fpage>–201.</mixed-citation>
</ref>
<ref id="bib10">
<mixed-citation publication-type="journal">Herbert MR. <article-title>Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders</article-title>. <source/>Curr Opin Neurol
<year>2010</year>; <volume>23</volume>: <fpage>103</fpage>–110.<pub-id pub-id-type="pmid">20087183</pub-id></mixed-citation>
</ref>
<ref id="bib11">
<mixed-citation publication-type="journal">Rossignol DA, Genuis SJ, Frye RE. <article-title>Environmental toxicants and autism spectrum disorders: a systematic review</article-title>. <source/>Transl Psychiatry
<year>2014</year>; <volume>4</volume>: <fpage>e360</fpage>.<pub-id pub-id-type="pmid">24518398</pub-id></mixed-citation>
</ref>
<ref id="bib12">
<mixed-citation publication-type="journal">Lanni KE, Schupp CW, Simon D, Corbett BA. <article-title>Verbal ability, social stress, and anxiety in children with autistic disorder</article-title>. <source/>Autism
<year>2012</year>; <volume>16</volume>: <fpage>123</fpage>–138.<pub-id pub-id-type="pmid">22087042</pub-id></mixed-citation>
</ref>
<ref id="bib13">
<mixed-citation publication-type="journal">Theoharides TC, Weinkauf C, Conti P. <article-title>Brain cytokines and neuropsychiatric disorders</article-title>. <source/>J Clin Psychopharmacol
<year>2004</year>; <volume>24</volume>: <fpage>577</fpage>–581.<pub-id pub-id-type="pmid">15538117</pub-id></mixed-citation>
</ref>
<ref id="bib14">
<mixed-citation publication-type="journal">Buie T, Campbell DB, Fuchs GJ III, Furuta GT, Levy J, Vandewater J et al. <article-title>Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report</article-title>. <source/>Pediatrics
<year>2010</year>; <volume>125</volume>: <fpage>S1</fpage>–18.<pub-id pub-id-type="pmid">20048083</pub-id></mixed-citation>
</ref>
<ref id="bib15">
<mixed-citation publication-type="journal">Rossignol DA, Frye RE. <article-title>Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis</article-title>. <source/>Mol Psychiatry
<year>2012</year>; <volume>17</volume>: <fpage>290</fpage>–314.<pub-id pub-id-type="pmid">21263444</pub-id></mixed-citation>
</ref>
<ref id="bib16">
<mixed-citation publication-type="journal">Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M et al. <article-title>Brief report: ‘allergic symptoms’ in children with autism spectrum disorders. More than meets the eye</article-title>? <source/>J Autism Dev Disord
<year>2011</year>; <volume>41</volume>: <fpage>1579</fpage>–1585.<pub-id pub-id-type="pmid">21210299</pub-id></mixed-citation>
</ref>
<ref id="bib17">
<mixed-citation publication-type="journal">Gurney JG, McPheeters ML, Davis MM. <article-title>Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health</article-title>. <source/>Arch Pediatr Adolesc Med
<year>2006</year>; <volume>160</volume>: <fpage>825</fpage>–830.<pub-id pub-id-type="pmid">16894082</pub-id></mixed-citation>
</ref>
<ref id="bib18">
<mixed-citation publication-type="journal">Theoharides TC, Zhang B. <article-title>Neuro-Inflammation, blood-brain barrier, seizures and autism</article-title>. <source/>J Neuroinflamm
<year>2011</year>; <volume>8</volume>: <fpage>168</fpage>.</mixed-citation>
</ref>
<ref id="bib19">
<mixed-citation publication-type="journal">Hagberg H, Gressens P, Mallard C. <article-title>Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults</article-title>. <source/>Ann Neurol
<year>2012</year>; <volume>71</volume>: <fpage>444</fpage>–457.<pub-id pub-id-type="pmid">22334391</pub-id></mixed-citation>
</ref>
<ref id="bib20">
<mixed-citation publication-type="journal">Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J et al. <article-title>Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism</article-title>. <source/>Nat Commun
<year>2014</year>; <volume>5</volume>: <fpage>5748</fpage>.<pub-id pub-id-type="pmid">25494366</pub-id></mixed-citation>
</ref>
<ref id="bib21">
<mixed-citation publication-type="journal">Skaper SD, Facci L, Giusti P. <article-title>Mast cells, glia and neuroinflammation: partners in crime</article-title>? <source/>Immunology
<year>2014</year>; <volume>141</volume>: <fpage>314</fpage>–327.<pub-id pub-id-type="pmid">24032675</pub-id></mixed-citation>
</ref>
<ref id="bib22">
<mixed-citation publication-type="journal">Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E et al. <article-title>Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects</article-title>. <source/>Endocrinology
<year>1998</year>; <volume>139</volume>: <fpage>403</fpage>–413.<pub-id pub-id-type="pmid">9421440</pub-id></mixed-citation>
</ref>
<ref id="bib23">
<mixed-citation publication-type="journal">Theoharides TC. <article-title>Autism spectrum disorders and mastocytosis</article-title>. <source/>Int J Immunopathol Pharmacol
<year>2009</year>; <volume>22</volume>: <fpage>859</fpage>–865.<pub-id pub-id-type="pmid">20074449</pub-id></mixed-citation>
</ref>
<ref id="bib24">
<mixed-citation publication-type="journal">Theoharides TC, Valent P, Akin C. <article-title>Mast cells, mastocytosis and related diseases</article-title>. <source/>N Engl J Med
<year>2015</year>; <volume>373</volume>: <fpage>163</fpage>–172.<pub-id pub-id-type="pmid">26154789</pub-id></mixed-citation>
</ref>
<ref id="bib25">
<mixed-citation publication-type="journal">Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A et al. <article-title>Neurotensin is increased in serum of young children with autistic disorder</article-title>. <source/>J Neuroinflamm
<year>2010</year>; <volume>7</volume>: <fpage>48</fpage>.</mixed-citation>
</ref>
<ref id="bib26">
<mixed-citation publication-type="journal">Carraway R, Leeman SE. <article-title>The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami</article-title>. <source/>J Biol Chem
<year>1973</year>; <volume>248</volume>: <fpage>6854</fpage>–6861.<pub-id pub-id-type="pmid">4745447</pub-id></mixed-citation>
</ref>
<ref id="bib27">
<mixed-citation publication-type="journal">Mustain WC, Rychahou PG, Evers BM. <article-title>The role of neurotensin in physiologic and pathologic processes</article-title>. <source/>Curr Opin Endocrinol Diabetes Obes
<year>2011</year>; <volume>18</volume>: <fpage>75</fpage>–82.<pub-id pub-id-type="pmid">21124211</pub-id></mixed-citation>
</ref>
<ref id="bib28">
<mixed-citation publication-type="journal">Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli AA et al. <article-title>Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing bull terriers with a phenotype similar to autism</article-title>. <source/>Transl Psychiatry
<year>2014</year>; <volume>4</volume>: <fpage>e466</fpage>.<pub-id pub-id-type="pmid">25313509</pub-id></mixed-citation>
</ref>
<ref id="bib29">
<mixed-citation publication-type="journal">Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. <article-title>Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process</article-title>. <source/>Proc Natl Acad Sci USA
<year>2006</year>; <volume>103</volume>: <fpage>7759</fpage>–7764.<pub-id pub-id-type="pmid">16682628</pub-id></mixed-citation>
</ref>
<ref id="bib30">
<mixed-citation publication-type="other">Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. <article-title>Mast cells, brain inflammation and autism</article-title>. <source/>Eur J Pharmacol
<year>2015</year> pii: S0014-2999(15)00398-2.</mixed-citation>
</ref>
<ref id="bib31">
<mixed-citation publication-type="journal">Kritas SK, Saggini A, Cerulli G, Caraffa A, Antinolfi P, Pantalone A et al. <article-title>Corticotropin-releasing hormone, microglia and mental disorders</article-title>. <source/>Int J Immunopathol Pharmacol
<year>2014</year>; <volume>27</volume>: <fpage>163</fpage>–167.<pub-id pub-id-type="pmid">25004828</pub-id></mixed-citation>
</ref>
<ref id="bib32">
<mixed-citation publication-type="journal">Theoharides TC. <article-title>Is a subtype of autism an ‘allergy of the brain’</article-title>? <source/>Clin Ther
<year>2013</year>; <volume>35</volume>: <fpage>584</fpage>–591.<pub-id pub-id-type="pmid">23688533</pub-id></mixed-citation>
</ref>
<ref id="bib33">
<mixed-citation publication-type="journal">Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K et al. <article-title>Mast cell activation and autism</article-title>. <source/>Biochim Biophys Acta
<year>2012</year>; <volume>1822</volume>: <fpage>34</fpage>–41.<pub-id pub-id-type="pmid">21193035</pub-id></mixed-citation>
</ref>
<ref id="bib34">
<mixed-citation publication-type="journal">Middleton EJ, Kandaswami C, Theoharides TC. <article-title>The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer</article-title>. <source/>Pharmacol Rev
<year>2000</year>; <volume>52</volume>: <fpage>673</fpage>–751.<pub-id pub-id-type="pmid">11121513</pub-id></mixed-citation>
</ref>
<ref id="bib35">
<mixed-citation publication-type="journal">Weng Z, Patel A, Panagiotidou S, Theoharidess TC. <article-title>The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells</article-title>. <source/>J Allergy Clin Immunol
<year>2014</year>; <volume>14</volume>: <fpage>1044</fpage>–1052.</mixed-citation>
</ref>
<ref id="bib36">
<mixed-citation publication-type="journal">Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N et al. <article-title>Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells</article-title>. <source/>Br J Pharmacol
<year>2005</year>; <volume>145</volume>: <fpage>934</fpage>–944.<pub-id pub-id-type="pmid">15912140</pub-id></mixed-citation>
</ref>
<ref id="bib37">
<mixed-citation publication-type="journal">Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ et al. <article-title>Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells</article-title>. <source/>Arch Pharm Res
<year>2008</year>; <volume>31</volume>: <fpage>1303</fpage>–1311.<pub-id pub-id-type="pmid">18958421</pub-id></mixed-citation>
</ref>
<ref id="bib38">
<mixed-citation publication-type="journal">Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. <article-title>Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells</article-title>. <source/>Clin Exp Allergy
<year>2000</year>; <volume>30</volume>: <fpage>501</fpage>–508.<pub-id pub-id-type="pmid">10718847</pub-id></mixed-citation>
</ref>
<ref id="bib39">
<mixed-citation publication-type="journal">Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P et al. <article-title>Luteolin inhibits mast cell-mediated allergic inflammation</article-title>. <source/>J Biol Regul Homeost Agents
<year>2013</year>; <volume>27</volume>: <fpage>955</fpage>–959.<pub-id pub-id-type="pmid">24382176</pub-id></mixed-citation>
</ref>
<ref id="bib40">
<mixed-citation publication-type="journal">Jang S, Kelley KW, Johnson RW. <article-title>Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1</article-title>. <source/>Proc Natl Acad Sci USA
<year>2008</year>; <volume>105</volume>: <fpage>7534</fpage>–7539.<pub-id pub-id-type="pmid">18490655</pub-id></mixed-citation>
</ref>
<ref id="bib41">
<mixed-citation publication-type="journal">Parker-Athill E, Luo D, Bailey A, Giunta B, Tian J, Shytle RD et al. <article-title>Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism</article-title>. <source/>J Neuroimmunol
<year>2009</year>; <volume>217</volume>: <fpage>20</fpage>–27.<pub-id pub-id-type="pmid">19766327</pub-id></mixed-citation>
</ref>
<ref id="bib42">
<mixed-citation publication-type="journal">Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W et al. <article-title>Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells</article-title>. <source/>Br J Pharmacol
<year>2008</year>; <volume>155</volume>: <fpage>1076</fpage>–1084.<pub-id pub-id-type="pmid">18806808</pub-id></mixed-citation>
</ref>
<ref id="bib43">
<mixed-citation publication-type="journal">Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. <article-title>Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation</article-title>. <source/>Neurosci Lett
<year>2008</year>; <volume>448</volume>: <fpage>175</fpage>–179.<pub-id pub-id-type="pmid">18952146</pub-id></mixed-citation>
</ref>
<ref id="bib44">
<mixed-citation publication-type="journal">Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P et al. <article-title>Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection</article-title>. <source/>Brain Res Bull
<year>2007</year>; <volume>73</volume>: <fpage>55</fpage>–63.<pub-id pub-id-type="pmid">17499637</pub-id></mixed-citation>
</ref>
<ref id="bib45">
<mixed-citation publication-type="journal">Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y et al. <article-title>Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype</article-title>. <source/>J Neuroinflamm
<year>2010</year>; <volume>7</volume>: <fpage>3</fpage>.</mixed-citation>
</ref>
<ref id="bib46">
<mixed-citation publication-type="journal">Jang S, Dilger RN, Johnson RW. <article-title>Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice</article-title>. <source/>J Nutr
<year>2010</year>; <volume>140</volume>: <fpage>1892</fpage>–1898.<pub-id pub-id-type="pmid">20685893</pub-id></mixed-citation>
</ref>
<ref id="bib47">
<mixed-citation publication-type="journal">Kao TK, Ou YC, Lin SY, Pan HC, Song PJ, Raung SL et al. <article-title>Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia</article-title>. <source/>J Nutr Biochem
<year>2011</year>; <volume>22</volume>: <fpage>612</fpage>–624.<pub-id pub-id-type="pmid">21036586</pub-id></mixed-citation>
</ref>
<ref id="bib48">
<mixed-citation publication-type="journal">Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD et al. <article-title>Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells</article-title>. <source/>Int J Immunopathol Pharmacol
<year>2010</year>; <volume>23</volume>: <fpage>1015</fpage>–1020.<pub-id pub-id-type="pmid">21244751</pub-id></mixed-citation>
</ref>
<ref id="bib49">
<mixed-citation publication-type="journal">Franco JL, Posser T, Missau F, Pizzolatti MG, Dos Santos AR, Souza DO et al. <article-title>Structure-activity relationship of flavonoids derived from medicinal plants in preventing methylmercury-induced mitochondrial dysfunction</article-title>. <source/>Environ Toxicol Pharmacol
<year>2010</year>; <volume>30</volume>: <fpage>272</fpage>–278.<pub-id pub-id-type="pmid">21127717</pub-id></mixed-citation>
</ref>
<ref id="bib50">
<mixed-citation publication-type="journal">Taliou A, Zintzaras E, Lykouras L, Francis K. <article-title>An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders</article-title>. <source/>Clin Ther
<year>2013</year>; <volume>35</volume>: <fpage>592</fpage>–602.<pub-id pub-id-type="pmid">23688534</pub-id></mixed-citation>
</ref>
<ref id="bib51">
<mixed-citation publication-type="journal">Kempuraj D, Konstantinidou A, Boscolo P, Ferro F, Di Giannantonio M, Conti CM et al. <article-title>Cytokines and the brain</article-title>. <source/>Int J Immunopathol Pharmacol
<year>2004</year>; <volume>17</volume>: <fpage>229</fpage>–232.<pub-id pub-id-type="pmid">15461855</pub-id></mixed-citation>
</ref>
<ref id="bib52">
<mixed-citation publication-type="journal">Xu N, Li X, Zhong Y. <article-title>Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders</article-title>. <source/>Mediators Inflamm
<year>2015</year>; <volume>2015</volume>: <fpage>531518</fpage>.<pub-id pub-id-type="pmid">25729218</pub-id></mixed-citation>
</ref>
<ref id="bib53">
<mixed-citation publication-type="journal">Tonhajzerova I, Ondrejka I, Mestanik M, Mikolka P, Hrtanek I, Mestanikova A et al. <article-title>Inflammatory activity in autism spectrum disorder</article-title>. <source/>Adv Exp Med Biol
<year>2015</year>; <volume>861</volume>: <fpage>93</fpage>–98.<pub-id pub-id-type="pmid">26022900</pub-id></mixed-citation>
</ref>
<ref id="bib54">
<mixed-citation publication-type="journal">Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de WJ. <article-title>Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome</article-title>. <source/>Brain Behav Immun
<year>2011</year>; <volume>25</volume>: <fpage>40</fpage>–45.<pub-id pub-id-type="pmid">20705131</pub-id></mixed-citation>
</ref>
<ref id="bib55">
<mixed-citation publication-type="journal">Yirmiya R, Goshen I. <article-title>Immune modulation of learning, memory, neural plasticity and neurogenesis</article-title>. <source/>Brain Behav Immun
<year>2011</year>; <volume>25</volume>: <fpage>181</fpage>–213.<pub-id pub-id-type="pmid">20970492</pub-id></mixed-citation>
</ref>
<ref id="bib56">
<mixed-citation publication-type="journal">Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K et al. <article-title>Immune transcriptome alterations in the temporal cortex of subjects with autism</article-title>. <source/>Neurobiol Dis
<year>2008</year>; <volume>30</volume>: <fpage>303</fpage>–311.<pub-id pub-id-type="pmid">18378158</pub-id></mixed-citation>
</ref>
<ref id="bib57">
<mixed-citation publication-type="journal">Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. <article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>. <source/>Ann Neurol
<year>2005</year>; <volume>57</volume>: <fpage>67</fpage>–81.<pub-id pub-id-type="pmid">15546155</pub-id></mixed-citation>
</ref>
<ref id="bib58">
<mixed-citation publication-type="journal">Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM et al. <article-title>Elevated immune response in the brain of autistic patients</article-title>. <source/>J Neuroimmunol
<year>2009</year>; <volume>207</volume>: <fpage>111</fpage>–116.<pub-id pub-id-type="pmid">19157572</pub-id></mixed-citation>
</ref>
<ref id="bib59">
<mixed-citation publication-type="journal">Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. <article-title>Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis</article-title>. <source/>Mol Psychiatry
<year>2015</year>; <volume>20</volume>: <fpage>440</fpage>–446.<pub-id pub-id-type="pmid">24934179</pub-id></mixed-citation>
</ref>
<ref id="bib60">
<mixed-citation publication-type="journal">Huang M, Pang X, Karalis K, Theoharides TC. <article-title>Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice</article-title>. <source/>Cardiovasc Res
<year>2003</year>; <volume>59</volume>: <fpage>241</fpage>–249.<pub-id pub-id-type="pmid">12829195</pub-id></mixed-citation>
</ref>
<ref id="bib61">
<mixed-citation publication-type="journal">Kandere-Grzybowska K, Kempuraj D, Letourneau L, Asare A, Athanasiou A, Theoharides TC. <article-title>IL-1 induces differential release of IL-6 form human mast cells</article-title>. <source/>FASEB J
<year>2002</year>; <volume>16</volume>: <fpage>A332</fpage>.</mixed-citation>
</ref>
<ref id="bib62">
<mixed-citation publication-type="journal">Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de WJ. <article-title>Altered T cell responses in children with autism</article-title>. <source/>Brain Behav Immun
<year>2011</year>; <volume>25</volume>: <fpage>840</fpage>–849.<pub-id pub-id-type="pmid">20833247</pub-id></mixed-citation>
</ref>
<ref id="bib63">
<mixed-citation publication-type="journal">Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. <article-title>Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children</article-title>. <source/>Pediatr Neurol
<year>2007</year>; <volume>36</volume>: <fpage>361</fpage>–365.<pub-id pub-id-type="pmid">17560496</pub-id></mixed-citation>
</ref>
<ref id="bib64">
<mixed-citation publication-type="journal">Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D. <article-title>Evidence that brain mast cells can modulate neuroinflammatory responses by tumor necrosis factor-α production</article-title>. <source/>Neuroreport
<year>1998</year>; <volume>9</volume>: <fpage>95</fpage>–98.<pub-id pub-id-type="pmid">9592055</pub-id></mixed-citation>
</ref>
<ref id="bib65">
<mixed-citation publication-type="journal">Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A et al. <article-title>Cerebrospinal fluid and serum markers of inflammation in autism</article-title>. <source/>Pediatr Neurol
<year>2005</year>; <volume>33</volume>: <fpage>195</fpage>–201.<pub-id pub-id-type="pmid">16139734</pub-id></mixed-citation>
</ref>
<ref id="bib66">
<mixed-citation publication-type="journal">Zhang B, Alysandratos KD, Angelidou A, Asadi S, Sismanopoulos N, Delivanis DA et al. <article-title>Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis</article-title>. <source/>J Allergy Clin Immunol
<year>2011</year>; <volume>127</volume>: <fpage>1522</fpage>–1531.<pub-id pub-id-type="pmid">21453958</pub-id></mixed-citation>
</ref>
<ref id="bib67">
<mixed-citation publication-type="journal">Olszewski MB, Groot AJ, Dastych J, Knol EF. <article-title>TNF trafficking to human mast cell granules: mature chain-dependent endocytosis</article-title>. <source/>J Immunol
<year>2007</year>; <volume>178</volume>: <fpage>5701</fpage>–5709.<pub-id pub-id-type="pmid">17442953</pub-id></mixed-citation>
</ref>
<ref id="bib68">
<mixed-citation publication-type="journal">Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. <article-title>Mast cells enhance T cell activation: Importance of mast cell-derived TNF</article-title>. <source/>Proc Natl Acad Sci USA
<year>2005</year>; <volume>102</volume>: <fpage>6467</fpage>–6472.<pub-id pub-id-type="pmid">15840716</pub-id></mixed-citation>
</ref>
<ref id="bib69">
<mixed-citation publication-type="journal">Gilmore JH, Jarskog LF, Vadlamudi S. <article-title>Maternal poly I:C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat</article-title>. <source/>J Neuroimmunol
<year>2005</year>; <volume>159</volume>: <fpage>106</fpage>–112.<pub-id pub-id-type="pmid">15652408</pub-id></mixed-citation>
</ref>
<ref id="bib70">
<mixed-citation publication-type="journal">Al-Ayadhi LY, Mostafa GA. <article-title>Elevated serum levels of interleukin-17 A in children with autism</article-title>. <source/>J Neuroinflamm
<year>2012</year>; <volume>9</volume>: <fpage>158</fpage>.</mixed-citation>
</ref>
<ref id="bib71">
<mixed-citation publication-type="journal">Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Pawlowski T, Ober-Reynolds S et al. <article-title>Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder</article-title>. <source/>J Neuroinflamm
<year>2013</year>; <volume>10</volume>: <fpage>38</fpage>.</mixed-citation>
</ref>
<ref id="bib72">
<mixed-citation publication-type="journal">Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V et al. <article-title>IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation</article-title>. <source/>J Immunol
<year>2012</year>; <volume>188</volume>: <fpage>6287</fpage>–6299.<pub-id pub-id-type="pmid">22566565</pub-id></mixed-citation>
</ref>
<ref id="bib73">
<mixed-citation publication-type="journal">Dudeck A, Suender CA, Kostka SL, von SE, Maurer M. <article-title>Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function</article-title>. <source/>Eur J Immunol
<year>2011</year>; <volume>41</volume>: <fpage>1883</fpage>–1893.<pub-id pub-id-type="pmid">21491417</pub-id></mixed-citation>
</ref>
<ref id="bib74">
<mixed-citation publication-type="journal">Kenna TJ, Brown MA. <article-title>The role of IL-17-secreting mast cells in inflammatory joint disease</article-title>. <source/>Nat Rev Rheumatol
<year>2013</year>; <volume>9</volume>: <fpage>375</fpage>–379.<pub-id pub-id-type="pmid">23229447</pub-id></mixed-citation>
</ref>
<ref id="bib75">
<mixed-citation publication-type="journal">Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y et al. <article-title>A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone</article-title>. <source/>Proc Natl Acad Sci USA
<year>2010</year>; <volume>107</volume>: <fpage>2687</fpage>–2692.<pub-id pub-id-type="pmid">20133810</pub-id></mixed-citation>
</ref>
<ref id="bib76">
<mixed-citation publication-type="journal">Johnson RA, Lam M, Punzo AM, Li H, Lin BR, Ye K et al. <article-title>7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome</article-title>. <source/>J Appl Physiol
<year>2012</year>; <volume>112</volume>: <fpage>704</fpage>–710.<pub-id pub-id-type="pmid">22194327</pub-id></mixed-citation>
</ref>
<ref id="bib77">
<mixed-citation publication-type="journal">Theoharides T, Athanassiou M, Panagiotidou S, Doyle R. <article-title>Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders</article-title>. <source/>J Neuroimmunol
<year>2015</year>; <volume>279</volume>: <fpage>33</fpage>–38.<pub-id pub-id-type="pmid">25669997</pub-id></mixed-citation>
</ref>
<ref id="bib78">
<mixed-citation publication-type="journal">Harwood M, nielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. <article-title>A critical review of the data related to the safety of quercetin and lack of evidence of <italic>in vivo</italic> toxicity, including lack of genotoxic/carcinogenic properties</article-title>. <source/>Food Chem Toxicol
<year>2007</year>; <volume>45</volume>: <fpage>2179</fpage>–2205.<pub-id pub-id-type="pmid">17698276</pub-id></mixed-citation>
</ref>
<ref id="bib79">
<mixed-citation publication-type="journal">Kawanishi S, Oikawa S, Murata M. <article-title>Evaluation for safety of antioxidant chemopreventive agents</article-title>. <source/>Antioxid Redox Signal
<year>2005</year>; <volume>7</volume>: <fpage>1728</fpage>–1739.<pub-id pub-id-type="pmid">16356133</pub-id></mixed-citation>
</ref>
<ref id="bib80">
<mixed-citation publication-type="journal">Li L, Gu L, Chen Z, Wang R, Ye J, Jiang H. <article-title>Toxicity study of ethanolic extract of Chrysanthemum morifolium in rats</article-title>. <source/>J Food Sci
<year>2010</year>; <volume>75</volume>: <fpage>T105</fpage>–T109.<pub-id pub-id-type="pmid">20722958</pub-id></mixed-citation>
</ref>
<ref id="bib81">
<mixed-citation publication-type="journal">Jager AK, Saaby L. <article-title>Flavonoids and the CNS</article-title>. <source/>Molecules
<year>2011</year>; <volume>16</volume>: <fpage>1471</fpage>–1485.<pub-id pub-id-type="pmid">21311414</pub-id></mixed-citation>
</ref>
<ref id="bib82">
<mixed-citation publication-type="journal">Chen Z, Zheng S, Li L, Jiang H. <article-title>Metabolism of flavonoids in human: a comprehensive review</article-title>. <source/>Curr Drug Metab
<year>2014</year>; <volume>15</volume>: <fpage>48</fpage>–61.<pub-id pub-id-type="pmid">24588554</pub-id></mixed-citation>
</ref>
<ref id="bib83">
<mixed-citation publication-type="journal">Hollman PC, Katan MB. <article-title>Absorption, metabolism and health effects of dietary flavonoids in man</article-title>. <source/>Biomed Pharmacother
<year>1997</year>; <volume>51</volume>: <fpage>305</fpage>–310.<pub-id pub-id-type="pmid">9436520</pub-id></mixed-citation>
</ref>
<ref id="bib84">
<mixed-citation publication-type="journal">Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB. <article-title>Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers</article-title>. <source/>Am J Clin Nutr
<year>1995</year>; <volume>62</volume>: <fpage>1276</fpage>–1282.<pub-id pub-id-type="pmid">7491892</pub-id></mixed-citation>
</ref>
<ref id="bib85">
<mixed-citation publication-type="journal">Theoharides TC, Asadi S. <article-title>Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders</article-title>. <source/>J Clin Psychopharmacol
<year>2012</year>; <volume>32</volume>: <fpage>437</fpage>–440.<pub-id pub-id-type="pmid">22722515</pub-id></mixed-citation>
</ref>
<ref id="bib86">
<mixed-citation publication-type="journal">Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC et al. <article-title>Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain</article-title>. <source/>Mol Ther
<year>2011</year>; <volume>19</volume>: <fpage>1769</fpage>–1779.<pub-id pub-id-type="pmid">21915101</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1">
<label>Figure 1</label>
<caption>
<p>(<bold>a</bold>) Comparison of serum IL-6 levels in normal and ASDs children. (<bold>b</bold>) Serum IL-6 levels in children with ASDs before and after treatment with a luteolin-containing dietary formulation. Symbols represent individual data points, and the horizontal line represents the mean for each group. ASD, autism spectrum disorder; IL, interleukin.</p>
</caption>
<graphic xlink:href="tp2015142f1" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</fig>
<fig id="fig2">
<label>Figure 2</label>
<caption>
<p>(<bold>a</bold>) Comparison of serum TNF levels in normal and ASDs children. (<bold>b</bold>) Serum TNF levels in children with ASDs before and after treatment with a luteolin-containing dietary formulation. Symbols represent individual data points, and the horizontal line represents the mean for each group. ASD, autism spectrum disorder; TNF, tumor necrosis factor.</p>
</caption>
<graphic xlink:href="tp2015142f2" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</fig>
<table-wrap id="tbl1">
<label>Table 1</label>
<caption>
<title>Effectiveness of the study luteolin formulation in ASDs children with high serum IL-6 and TNF levels (<italic>n</italic>=10)</title>
</caption>
<table border="1" frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead valign="bottom">
<tr>
<th align="left" charoff="50" valign="top">
<italic>Vineland adaptive behavior scales (VABS)</italic>
</th>
<th align="center" char="." charoff="50" valign="top">
<italic>0 week</italic>
</th>
<th align="center" char="." charoff="50" valign="top">
<italic>26 week</italic>
</th>
<th align="center" char="." charoff="50" valign="top">
<italic>Change</italic>
</th>
<th align="center" char="." charoff="50" valign="top">
<italic>Effect size<xref ref-type="fn" rid="t1-fn2">a</xref></italic>
</th>
<th align="center" char="." charoff="50" valign="top">P<italic>-value</italic></th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" charoff="50" valign="top">Communication AE</td>
<td align="char" char="." charoff="50" valign="top">38.91 (25.47)<xref ref-type="fn" rid="t1-fn3">b</xref></td>
<td align="char" char="." charoff="50" valign="top">48.64 (31.60)</td>
<td align="char" char="." charoff="50" valign="top">9.73</td>
<td align="char" char="." charoff="50" valign="top">0.38</td>
<td align="char" char="." charoff="50" valign="top">0.008</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Daily living skills AE</td>
<td align="char" char="." charoff="50" valign="top">38.45 (19.11)</td>
<td align="char" char="." charoff="50" valign="top">45.09 (21.00)</td>
<td align="char" char="." charoff="50" valign="top">6.64</td>
<td align="char" char="." charoff="50" valign="top">0.35</td>
<td align="char" char="." charoff="50" valign="top">0.0003</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Social AE</td>
<td align="char" char="." charoff="50" valign="top">36.55 (18.04)</td>
<td align="char" char="." charoff="50" valign="top">44.64 (20.93)</td>
<td align="char" char="." charoff="50" valign="top">8.09</td>
<td align="char" char="." charoff="50" valign="top">0.45</td>
<td align="char" char="." charoff="50" valign="top">0.001</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Composite score</td>
<td align="char" char="." charoff="50" valign="top">37.97 (19.68)</td>
<td align="char" char="." charoff="50" valign="top">46.12 (23.19)</td>
<td align="char" char="." charoff="50" valign="top">8.15</td>
<td align="char" char="." charoff="50" valign="top">0.42</td>
<td align="char" char="." charoff="50" valign="top">0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t1-fn1">
<p>Abbreviations: AE, age equivalent; ASD, autism spectrum disorder; IL, interleukin; TNF, tumor necrosis factor; VABS, Vineland Adaptive Behavior Scale.</p>
</fn>
<fn id="t1-fn2">
<label>a</label>
<p>(26 week–0 week)/0 week s.d.</p>
</fn>
<fn id="t1-fn3">
<label>b</label>
<p>VABS scores (s.d.).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>